Soterios is developing the first safe, topical, treatment for mild/moderate alopecia areata (patients who have lost less than 50% of their hair), an indication that currently has no approved treatments and affects over 400,000 patients in the US alone.

Soterios completed a phase II clinical trial in 155 patients and demonstrated significant efficacy over placebo with no safety concerns.